Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 157496, 5 pages
http://dx.doi.org/10.1155/2012/157496
Review Article

Bone Marrow Microenvironment in Multiple Myeloma Progression

1Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, 450 Brookline Avnue, HIM 246, Boston, MA 02215, USA
2Service des Maladies du Sang, CHRU de Lille, 59000 Lille, France

Received 3 August 2012; Accepted 18 September 2012

Academic Editor: Sue-Hwa Lin

Copyright © 2012 S. Manier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [107 citations]

The following is the list of published articles that have cited the current article.

  • Agnes D. Berendsen, and Bjorn R. Olsen, “Osteoblast–adipocyte lineage plasticity in tissue development, maintenance and pathology,” Cellular and Molecular Life Sciences, 2013. View at Publisher · View at Google Scholar
  • H. Lokhorst, A. Palumbo, H. Nahi, J. Laubach, P. Gimsing, S. Lisby, A. Cakana, N. Constantin Brun, and T. Plesner, “DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma,” Drugs of The Future, vol. 38, no. 8, pp. 545–554, 2013. View at Publisher · View at Google Scholar
  • Amit Sudhir Khot, H Miles Prince, Simon James Harrison, and John Francis Seymour, “Myeloma and Pregnancy: Strange Bedfellows?,” Leukemia & Lymphoma, pp. 1–7, 2013. View at Publisher · View at Google Scholar
  • Tina W. Wong, Hirohito Kita, Curtis A. Hanson, Denise K. Walters, Bonnie K. Arendt, and Diane F. Jelinek, “Induction of Malignant Plasma Cell Proliferation by Eosinophils,” PLoS ONE, vol. 8, no. 7, 2013. View at Publisher · View at Google Scholar
  • Sakshi Sikka, Muthu K. Shanmugam, Radhamani Kannaiyan, Rohit Surana, Eun Myoung Shin, Alan Prem Kumar, Gautam Sethi, and Kwang Seok Ahn, “Suppression of essential pro-inflammatory signaling pathways by natural agents for the therapy of Multiple Myeloma,” Phytochemistry Reviews, 2013. View at Publisher · View at Google Scholar
  • Zhiqiang Liu, Jingda Xu, Haiyan Li, Yuhuan Zheng, Jin He, Huan Liu, Yuping Zhong, Yong Lu, Bangxing Hong, Mingjun Zhang, Pei Lin, Juan Du, Jian Hou, Jianfei Qian, Larry W. Kwak, Qing Yi, and Jing Yang, “Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression,” Plos One, vol. 8, no. 12, 2013. View at Publisher · View at Google Scholar
  • Panisinee Lawasut, Richard W.J. Groen, Eugen Dhimolea, Paul G. Richardson, Kenneth C. Anderson, and Constantine S. Mitsiades, “Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets,” Seminars in Oncology, vol. 40, no. 5, pp. 537–548, 2013. View at Publisher · View at Google Scholar
  • Richardson, Plesne, Lokhorst, Palumbo, Nahi, Laubach, Gimsing, Lisby, Cakana, and Constantin Brun, “Daratumumab. Anti-CD38 monoclonal antibody, treatment of multiple myeloma,” Drugs of the Future, vol. 38, no. 8, pp. 545–554, 2013. View at Publisher · View at Google Scholar
  • Guoan Chen, Jahangir Abdi, and Hong Chang, “Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms,” Oncotarget, vol. 4, no. 12, pp. 2186–2207, 2013. View at Publisher · View at Google Scholar
  • Xiang-Li Li, Xiao-Ying Zhang, Li Zang, and Xiao-Fang Wang, “Different pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state,” Chinese Journal of Tissue Engineering Research, vol. 18, no. 37, pp. 5935–5941, 2014. View at Publisher · View at Google Scholar
  • Marzia Leotta, Lavinia Biamonte, Lavinia Raimondi, Domenica Ronchetti, Maria Teresa Di Martino, Cirino Botta, Emanuela Leone, Maria Rita Pitari, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri, Pierfrancesco Tassone, and Nicola Amodio, “A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells,” Journal of Cellular Physiology, vol. 229, no. 12, pp. 2106–2116, 2014. View at Publisher · View at Google Scholar
  • Adriana Zingone, Weixin Wang, Meghan Corrigan-Cummins, S. Peter Wu, Ryan Plyler, Neha Korde, Mary Kwok, Elisabet E. Manasanch, Nishant Tageja, Manisha Bhutani, Marcia Mulquin, Diamond Zuchlinski, Mary Ann Yancey, Mark Roschewski, Yong Zhang, Aldo M. Roccaro, Irene M. Ghobrial, Katherine R. Calvo, and Ola Landgren, “Altered cytokine and chemokine profiles in multiple myeloma and precursor disease,” Cytokine, 2014. View at Publisher · View at Google Scholar
  • Jinheng Wang, An Hendrix, Sophie Hernot, Miguel Lemaire, Elke De Bruyne, Els Van Valckenborgh, Tony Lahoutte, Olivier De Wever, Karin Vanderkerken, and Eline Menu, “Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells,” Blood, vol. 124, no. 4, pp. 555–566, 2014. View at Publisher · View at Google Scholar
  • Jinheng Wang, Eline Menu, Karin Vanderkerken, Tony Lahoutte, Olivier De Wever, An Hendrix, Sophie Hernot, Miguel Lemaire, Els Van Valckenborgh, and Elke De Bruyne, “Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells,” Blood, vol. 124, no. 4, pp. 555–566, 2014. View at Publisher · View at Google Scholar
  • Kim De Veirman, Luigia Rao, Elke De Bruyne, Eline Menu, Els Van Valckenborgh, Ivan Van Riet, Maria Frassanito, Lucia Di Marzo, Angelo Vacca, and Karin Vanderkerken, “Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma,” Cancers, vol. 6, no. 3, pp. 1363–1381, 2014. View at Publisher · View at Google Scholar
  • Nuozhou Wang, Patrick Bartlow, Qin Ouyang, and Xiang-Qun Xie, “Recent advances in antimultiple myeloma drug development,” Pharmaceutical Patent Analyst, vol. 3, no. 3, pp. 261–277, 2014. View at Publisher · View at Google Scholar
  • Shuang Wu, Wenjun Yu, Xiaoyan Qu, Rong Wang, Ji Xu, Qiguo Zhang, Jiaren Xu, and Jianyong Li, “Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation,” Journal of Hematology & Oncology, vol. 7, 2014. View at Publisher · View at Google Scholar
  • C. Hope, S. J. Ollar, E. Heninger, E. Hebron, J. L. Jensen, J. Kim, I. Maroulakou, S. Miyamoto, C. Leith, D. T. Yang, N. Callander, P. Hematti, M. Chesi, P. L. Bergsagel, and F. Asimakopoulos, “TPL2 kinase regulates the inflammatory milieu of the myeloma niche,” Blood, vol. 123, no. 21, pp. 3305–3315, 2014. View at Publisher · View at Google Scholar
  • X. Li, H. Miao, Y. Zhang, W. Li, Z. Li, Y. Zhou, L. Zhao, and Q. Guo, “Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway,” Archives of Toxicology, 2014. View at Publisher · View at Google Scholar
  • Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Liang Zhou, Leena E. Youssefian, Michael W. Sanderson, Wesley W. Bodie, Lora B. Kramer, Robert Z. Orlowski, and Steven Grant, “Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells,” Plos One, vol. 9, no. 3, 2014. View at Publisher · View at Google Scholar
  • Brandon R Shank, Victoria T. Brown, and Rowena N. Schwartz, “Multiple myeloma maintenance therapy: A review of the pharmacologic treatment,” Journal of Oncology Pharmacy Practice, vol. 21, no. 1, pp. 36–51, 2014. View at Publisher · View at Google Scholar
  • Dan Wu, Xinyi Guo, Jing Su, Ruoying Chen, Dmitriy Berenzon, Martin Guthold, Keith Bonin, Weiling Zhao, and Xiaobo Zhou, “CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014. View at Publisher · View at Google Scholar
  • Krishan K. Thakur, Nityanand B. Bolshette, Cristiana Trandafir, Vinayak S. Jamdade, Alexandru Istrate, Ranadeep Gogoi, and Andrei Cucuianu, “Role of toll-like receptors in multiple myeloma and recent advances,” Experimental Hematology, 2014. View at Publisher · View at Google Scholar
  • V Ramakrishnan, U Painuly, T Kimlinger, J Haug, S V Rajkumar, and S Kumar, “Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma,” Leukemia, 2014. View at Publisher · View at Google Scholar
  • Jahangir Abdi, Lugui Qiu, and Hong Chang, “Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment.,” Biomarker research, vol. 2, pp. 10, 2014. View at Publisher · View at Google Scholar
  • Alessandra Romano, Concetta Conticello, Maide Cavalli, Calogero Vetro, Alessia La Fauci, Nunziatina Laura Parrinello, and Francesco Di Raimondo, “Immunological Dysregulation in Multiple Myeloma Microenvironment,” BioMed Research International, vol. 2014, pp. 1–10, 2014. View at Publisher · View at Google Scholar
  • Roberto Ria, “Novel agents and new therapeutic approaches for treatment of multiple myeloma,” World Journal of Methodology, vol. 4, no. 2, pp. 73, 2014. View at Publisher · View at Google Scholar
  • Shang-Yi Huang, Hsiu-Hsia Lin, Ming Yao, Jih-Luh Tang, Shang-Ju Wu, Hsin-An Hou, Wen-Chien Chou, Sheng-Chieh Chou, Szu-Chun Hsu, Bor-Sheng Ko, Hsiao-Yun Lu, Woei Tsay, and Hwei-Fang Tien, “Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diag,” Plos One, vol. 10, no. 9, 2015. View at Publisher · View at Google Scholar
  • Weixin Wang, Meghan Corrigan-Cummins, Emily A. Barber, Layla M. Saleh, Adriana Zingone, Azam Ghafoor, Rene Costello, Yong Zhang, Roger J. Kurlander, Neha Korde, Aldo M. Roccaro, Irene M. Ghobrial, Ola Landgren, and Katherine R. Calvo, “Aberrant Level of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression,” The Journal of Molecular Diagnostics, 2015. View at Publisher · View at Google Scholar
  • Zhiwei Ji, Dan Wu, Weiling Zhao, Huiming Peng, Shengjie Zhao, Deshuang Huang, and Xiaobo Zhou, “Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach,” Scientific Reports, vol. 5, pp. 13291, 2015. View at Publisher · View at Google Scholar
  • Yanjie Li, Ning Li, Zhiling Yan, Hujun Li, Lili Chen, Zhiyao Zhang, Guoqin Fan, Kailin Xu, and Zhenyu Li, “Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma,” Hematology, vol. 21, no. 3, pp. 144–151, 2015. View at Publisher · View at Google Scholar
  • Pelin Mutlu, Yağmur Kiraz, Ufuk Gündüz, and Yusuf Baran, “An update on molecular biology and drug resistance mechanisms of multiple myeloma,” Critical Reviews in Oncology/Hematology, 2015. View at Publisher · View at Google Scholar
  • Jianfeng Guo, Sharon L McKenna, Michael E O’Dwyer, Mary R Cahill, and Caitriona M O’Driscoll, “RNA interference for multiple myeloma therapy: targeting signal transduction pathways,” Expert Opinion on Therapeutic Targets, vol. 20, no. 1, pp. 107–121, 2015. View at Publisher · View at Google Scholar
  • R. Jitumori, D. Fernandes, C. Jitumori, and G. M. Favero, “Simvastatin Protects Osteoblasts from the Deleterious Effects of the Liquid Milieu of Multiple Myeloma,” West Indian Medical Journal, vol. 64, no. 3, pp. 263–265, 2015. View at Publisher · View at Google Scholar
  • Akinori Wada, Aya Ito, Hirofumi Iitsuka, Koichi Tsuneyama, Takayoshi Miyazono, Jun Murakami, Naotoshi Shibahara, Hiroaki Sakurai, Ikuo Saiki, Takashi Nakayama, Osamu Yoshie, Keiichi Koizumi, and Toshiro Sugiyama, “Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments,” Oncology Reports, vol. 33, no. 6, pp. 2935–2939, 2015. View at Publisher · View at Google Scholar
  • Junya Kuroda, Tsutomu Kobayashi, and Masafumi Taniwaki, “Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy,” Expert Review of Anticancer Therapy, pp. 1–18, 2015. View at Publisher · View at Google Scholar
  • Manuela Gambella, Antonio Palumbo, and Alberto Rocci, “MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?,” Expert Review of Molecular Diagnostics, pp. 1–13, 2015. View at Publisher · View at Google Scholar
  • T. N. Trotter, M. Li, Q. Pan, D. Peker, P. D. Rowan, J. Li, F. Zhan, L. J. Suva, A. Javed, and Y. Yang, “Myeloma cell-derived Runx2 promotes myeloma progression in bone,” Blood, vol. 125, no. 23, pp. 3598–3608, 2015. View at Publisher · View at Google Scholar
  • Sabino Ciavarella, Anna Caselli, Antonella Valentina Tamma, Annalisa Savonarola, Giuseppe Loverro, Roberto Paganelli, Marco Tucci, and Franco Silvestris, “A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression,” Stem Cells and Development, pp. 150311105649008, 2015. View at Publisher · View at Google Scholar
  • Yasuyuki Nagata, Itsuko Ishizaki, Michihiko Waki, Yoshimi Ide, Md Amir Hossen, Kazunori Ohnishi, Takuya Miyayama, and Mitsutoshi Setou, “Palmitic acid, verified by lipid profiling using secondary ion mass spectrometry, demonstrates anti-multiple myeloma activity,” Leukemia Research, 2015. View at Publisher · View at Google Scholar
  • Guo Bo, Chen Mei Xia, Han Qing Wang, Fan Hui, Dai Han Ren, Zhang Wen Ying, Zhang Ya Jing, Wang Yao, Zhu Hong Li, and Han Wei Dong, “CD138-directed adoptive immunotherapy of Chimeric Antigen Receptor (CAR)-modified T cells for Multiple Myeloma,” Journal of Cellular Immunotherapy, 2015. View at Publisher · View at Google Scholar
  • Meerim Park, Chan-Jeoung Park, Seongsoo Jang, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Kyoujung Hwang, and Young Ho Lee, “Reduced Expression of Osteonectin and Increased Natural Killer Cells May Contribute to the Pathophysiology of Aplastic Anemia,” Applied Immunohistochemistry & Molecular Morphology, vol. 23, no. 2, pp. 139–145, 2015. View at Publisher · View at Google Scholar
  • Rimma Berenstein, Olga Blau, Axel Nogai, Marlies Waechter, Ekaterina Slonova, Martin Schmidt-Hieber, Annegret Kunitz, Antonio Pezzutto, Bernd Doerken, and Igor Wolfgang Blau, “Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region,” BMC Cancer, vol. 15, no. 1, 2015. View at Publisher · View at Google Scholar
  • Juliette M.C. Bouyssou, Irene M. Ghobrial, and Aldo M. Roccaro, “Targeting SDF-1 in multiple myeloma tumor microenvironment,” Cancer Letters, 2015. View at Publisher · View at Google Scholar
  • Rimma Berenstein, Axel Nogai, Marlies Waechter, Olga Blau, Aline Kuehnel, Martin Schmidt-Hieber, Annegret Kunitz, Antonio Pezzutto, Bernd Dörken, and Igor Wolfgang Blau, “Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223,” Molecular Carcinogenesis, 2015. View at Publisher · View at Google Scholar
  • Hervé Avet-Loiseau, and Jill Correpp. 1–13, 2015. View at Publisher · View at Google Scholar
  • Nidhi Gupta, Rehan Khan, Raman Kumar, Lalit Kumar, and Alpana Sharma, “Versican and its associated molecules: Potential diagnostic markers for multiple myeloma,” Clinica Chimica Acta, 2015. View at Publisher · View at Google Scholar
  • Ilaria Saltarella, Aurelia Lamanuzzi, Antonia Reale, Angelo Vacca, and Roberto Ria, “Identify multiple myeloma stem cells: Utopia?,” World journal of stem cells, vol. 7, no. 1, pp. 84–95, 2015. View at Publisher · View at Google Scholar
  • Alessandro Canella, Lara Rizzotto, Nicola Zanesi, Volinia Stefano, Balveen Kaur, Xiaokui Mo, John C. Byrd, Yvonne A. Efebera, Craig C. Hofmeister, Flavia Pichiorri, Hector Cordero Nieves, Douglas W. Sborov, Luciano Cascione, Hanna S. Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, and Enrico Caserta, “HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide,” Oncotarget, vol. 6, no. 31, pp. 31134–31150, 2015. View at Publisher · View at Google Scholar
  • Lu Lu, Qinglong Guo, and Li Zhao, “Overview of Oroxylin A: A Promising Flavonoid Compound,” Phytotherapy Research, 2016. View at Publisher · View at Google Scholar
  • Salomon Manier, Yawara Kawano, Giada Bianchi, Aldo M. Roccaro, and Irene M. Ghobrial, “Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma,” Current Opinion in Hematology, vol. 23, no. 4, pp. 426–433, 2016. View at Publisher · View at Google Scholar
  • Ross D. Brown, Sabna Rajeev Krishnan, Ritu Jaiswal, Frederick Luk, and Mary Bebawy, “Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review),” International Journal of Oncology, vol. 49, no. 1, pp. 33–50, 2016. View at Publisher · View at Google Scholar
  • Myriam Friedel, Sabine André, Hartmut Goldschmidt, Hans-Joachim Gabius, and Reinhard Schwartz-Albiez, “Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor,” Glycobiology, 2016. View at Publisher · View at Google Scholar
  • Gabriel M. Pagnotti, M. Ete Chan, Benjamin J. Adler, Kenneth R. Shroyer, Janet Rubin, Steven D. Bain, and Clinton T. Rubin, “Low Intensity Vibration Mitigates Tumor Progression and Protect Bone Quantity and Quality in a Murine Model of Myeloma,” Bone, 2016. View at Publisher · View at Google Scholar
  • Ehsan Malek, Marcos de Lima, John J. Letterio, Byung-Gyu Kim, James H. Finke, James J. Driscoll, and Sergio A. Giralt, “Myeloid-derived Suppressor Cells: The Green Light for Myeloma Immune Escape,” Blood Reviews, 2016. View at Publisher · View at Google Scholar
  • Valerie Sloane Jones, Ren-Yu Huang, Li-Pai Chen, Zhe-Sheng Chen, Liwu Fu, and Ruo-Pan Huang, “Cytokines in cancer drug resistance: Cues to new therapeutic strategies,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2016. View at Publisher · View at Google Scholar
  • H. Marcus, O. Attar-Schneider, M. Dabbah, V. Zismanov, S. Tartakover-Matalon, M. Lishner, and L. Drucker, “Mesenchymal stem cells secretomes' affect multiple myeloma translation initiation,” Cellular Signalling, 2016. View at Publisher · View at Google Scholar
  • Hua Wang, Liang Wang, Pei-dong Chi, Wei-da Wang, Xiao-qin Chen, Qi-rong Geng, Zhong-jun Xia, and Yue Lu, “High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma,” British Journal of Cancer, vol. 114, no. 4, pp. 463–468, 2016. View at Publisher · View at Google Scholar
  • Michael Low, Simona Infantino, George Grigoriadis, and David Tarlinton, “Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?,” Immunological Reviews, vol. 270, no. 1, pp. 78–94, 2016. View at Publisher · View at Google Scholar
  • I. Vardaki, C. Sanchez, P. Fonseca, M. Olsson, D. Chioureas, G. Rassidakis, A. Ullen, B. Zhivotovsky, M. Bjo rkholm, and T. Panaretakis, “Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells,” Blood, vol. 128, no. 23, pp. 2655–2665, 2016. View at Publisher · View at Google Scholar
  • Mahmoud Dabbah, Liat Drucker, Oshrat Attar-Schneider, Victoria Zismanov, Shelly Tartakover Matalon, and Michael Lishner, “Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation,” Journal of Leukocyte Biology, vol. 100, no. 4, pp. 761–770, 2016. View at Publisher · View at Google Scholar
  • Susan J. Lee, and Ivan Borrello, “Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma,” Plasma Cell Dyscrasias, vol. 169, pp. 207–225, 2016. View at Publisher · View at Google Scholar
  • S. W. Andrews, S. Kabrah, J. E. May, C. Donaldson, and H. R. Morse, “Multiple myeloma: the bone marrow microenvironment and its relation to treatment,” British Journal of Biomedical Science, vol. 70, no. 3, pp. 110–120, 2016. View at Publisher · View at Google Scholar
  • Alessandro Canella, Sean W. Harshman, Hanna S. Radomska, Michael A. Freitas, and Flavia Pichiorri, “The potential diagnostic power of extracellular vesicle analysis for multiple myeloma,” Expert Review of Molecular Diagnostics, pp. 1–8, 2016. View at Publisher · View at Google Scholar
  • Vanessa Desantis, Tiziana Annese, Beatrice Nico, Ruggiero Fumarulo, Lucia Di Marzo, Antonio Giovanni Solimando, Simona Ruggieri, Angelo Vacca, and Maria Antonia Frassanito, “Microenvironment drug resistance in multiple myeloma: Emerging new players,” Oncotarget, vol. 7, no. 37, pp. 60698–60711, 2016. View at Publisher · View at Google Scholar
  • Mingshan Niu, Kailin Xu, Min Shi, Lingyu Zeng, Ruosi Yao, Ying Zhang, Zhenyu Li, Yao Yao, Yueyue Sun, Dandan Xia, and Kai Zhao, “Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells,” Oncotarget, vol. 7, no. 45, pp. 73497–73508, 2016. View at Publisher · View at Google Scholar
  • Lavinia Raimondi, Angela De Luca, Eugenio Morelli, Gianluca Giavaresi, Pierosandro Tagliaferri, Pierfrancesco Tassone, and Nicola Amodio, “MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment,” BioMed Research International, vol. 2016, pp. 1–12, 2016. View at Publisher · View at Google Scholar
  • Prashant Kapoor, Ronald S. Go, Rafael Fonseca, P. Leif Bergsagel, Joseph R. Mikhael, A. Keith Stewart, Paul G. Richardson, Martha Q. Lacy, Betsy R. Laplant, Angela Dispenzieri, S. Vincent Rajkumar, Alese E. Halvorson, Shaji Kumar, Morie A. Gertz, Suzanne R. Hayman, Francis K. Buadi, Jonas Paludo, John A. Lust, Nelson Leung, Stephen J. Russell, David Dingli, Yi Lin, Wilson I. Gonsalves, Vivek Roy, Taimur Sher, Asher A. Chanan-Khan, Sikander Ailawadhi, and Craig B. Reeder, “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma,” Blood, vol. 130, no. 10, pp. 1198–1204, 2017. View at Publisher · View at Google Scholar
  • HongLiang Yang, YingChun Zheng, YiZhuo Zhang, Zeng Cao, and Yingzhe Jiang, “Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling,” Leukemia Research, vol. 60, pp. 82–88, 2017. View at Publisher · View at Google Scholar
  • Mohammad Alzrigat, Alba Atienza Párraga, and Helena Jernberg-Wiklund, “Epigenetics in Multiple Myeloma: From Mechanisms to Therapy,” Seminars in Cancer Biology, 2017. View at Publisher · View at Google Scholar
  • Shengli Li, Yang Jiang, Yaqi Xu, Yunliang Hao, Ai Li, Xiaoli Liu, Xiangling Xing, Yanan Guo, and Chengyun Zheng, “Telomere length is positively associated with the expression of IL-6 and MIP-1α in bone marrow mesenchymal stem cells of multiple myeloma,” Molecular Medicine Reports, vol. 16, no. 3, pp. 2497–2504, 2017. View at Publisher · View at Google Scholar
  • Xiaobo Zhang, Yicheng Liu, Lu Lu, Shaoliang Huang, Youxiang Ding, Yi Zhang, Qinglong Guo, Zhiyu Li, and Li Zhao, “Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway,” Frontiers in Pharmacology, vol. 8, 2017. View at Publisher · View at Google Scholar
  • Maria Margarida Tenreiro, Maria Leonor Correia, and Maria Alexandra Brito, “Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall,” Angiogenesis, 2017. View at Publisher · View at Google Scholar
  • Abhishek Das, Arghya Ray, Nikhil C. Munshi, Kenneth C. Anderson, Deepika Sharma Das, Yan Song, Mehmet Kemal Samur, and Dharminder Chauhan, “Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells,” Clinical Cancer Research, vol. 23, no. 15, pp. 4280–4289, 2017. View at Publisher · View at Google Scholar
  • Charlotte Pawlyn, and Gareth J. Morgan, “Evolutionary biology of high-risk multiple myeloma,” Nature Reviews Cancer, vol. 17, no. 9, pp. 543–556, 2017. View at Publisher · View at Google Scholar
  • Joel R. Wilmore, and David Allman, “Here, There, and Anywhere? Arguments for and against the Physical Plasma Cell Survival Niche,” The Journal of Immunology, vol. 199, no. 3, pp. 839–845, 2017. View at Publisher · View at Google Scholar
  • Ankit K. Dutta, Duncan R. Hewett, J. Lynn Fink, John P. Grady, and Andrew C. W. Zannettino, “Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma,” British Journal of Haematology, 2017. View at Publisher · View at Google Scholar
  • Tomohiro Umezu, Satoshi Imanishi, Kenko Azuma, Chiaki Kobayashi, Seiichiro Yoshizawa, Kazuma Ohyashiki, and Junko H. Ohyashiki, “Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis,” Blood Advances, vol. 1, no. 13, pp. 812–823, 2017. View at Publisher · View at Google Scholar
  • Lola Weiss, Eithan Galun, Amnon Peled, Evgenia Rosenberg, Avichai Shimoni, Merav Leiba, Maya Koren-Michowitz, Elena Ribakovsky, Devorah Olam, Katia Beider, Hanna Wald, Michal Abraham, Arnon Nagler, Hanna Bitner, and Shiri Klein, “The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway,” Clinical Cancer Research, vol. 23, no. 7, pp. 1733–1747, 2017. View at Publisher · View at Google Scholar
  • Gaurav Chatterjee, Sumeet Gujral, Papagudi G. Subramanian, and Prashant R. Tembhare, “Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders,” Indian Journal of Hematology and Blood Transfusion, 2017. View at Publisher · View at Google Scholar
  • S V Glavey, A Naba, S Manier, K Clauser, S Tahri, J Park, M R Reagan, M Moschetta, Y Mishima, M Gambella, A Rocci, A Sacco, M E O'Dwyer, J M Asara, A Palumbo, A M Roccaro, R O Hynes, and I M Ghobrial, “Proteomic characterization of human multiple myeloma bone marrow extracellular matrix,” Leukemia, vol. 31, no. 11, pp. 2426–2434, 2017. View at Publisher · View at Google Scholar
  • Anass Bouchnita, Fatima-Ezzahra Belmaati, Rajae Aboulaich, Mark Koury, and Vitaly Volpert, “A Hybrid Computation Model to Describe the Progression of Multiple Myeloma and Its Intra-Clonal Heterogeneity,” Computation, vol. 5, no. 1, pp. 16, 2017. View at Publisher · View at Google Scholar
  • Ivyna Pau Ni Bong, Ching Ching Ng, Puteri Baharuddin, and Zubaidah Zakaria, “MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy,” Genes & Genomics, vol. 39, no. 5, pp. 533–540, 2017. View at Publisher · View at Google Scholar
  • Nicholas Bingham, Antonia Reale, and Andrew Spencer, “An Evidence-Based Approach to Myeloma Bone Disease,” Current Hematologic Malignancy Reports, 2017. View at Publisher · View at Google Scholar
  • Mark E. Issa, Farnaz Sedigheh Takhsha, Chandra Sekhar Chirumamilla, Claudina Perez-Novo, Wim Vanden Berghe, and Muriel Cuendet, “Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma,” Clinical Epigenetics, vol. 9, no. 1, 2017. View at Publisher · View at Google Scholar
  • Chao-Feng Mu, Jianliang Shen, Jing Liang, Hang-Sheng Zheng, Yang Xiong, Ying-Hui Wei, and Fanzhu Li, “Targeted Drug Delivery for Tumor Therapy inside the Bone Marrow,” Biomaterials, 2017. View at Publisher · View at Google Scholar
  • Yu Sun, Amina Abdul Aziz, Kristian Bowles, and Stuart Rushworth, “High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma,” Cancer Letters, 2017. View at Publisher · View at Google Scholar
  • Sabrina Manni, Marilena Carrino, and Francesco Piazza, “Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways,” Journal of Hematology & Oncology, vol. 10, no. 1, 2017. View at Publisher · View at Google Scholar
  • Jie Jin, Tao Wang, Yu Wang, Shidi Chen, Zheng Li, Xiang Li, Jiazhen Zhang, and Jin Wang, “SRC3 expressed in BMSCs promotes growth and migration of multiple myeloma cells by regulating the expression of Cx43,” International Journal of Oncology, vol. 51, no. 6, pp. 1694–1704, 2017. View at Publisher · View at Google Scholar
  • Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, Maxwell D. Coll, Arie Apel, Hasan Rajabi, Athalia R. Pyzer, Kristen Palmer, Michaela R. Reagan, Myrna R. Nahas, Rebecca Karp Leaf, Salvia Jain, Jon Arnason, Irene M. Ghobrial, Kenneth C. Anderson, Donald Kufe, Jacalyn Rosenblatt, and David Avigan, “Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1,” British Journal of Haematology, vol. 176, no. 6, pp. 929–938, 2017. View at Publisher · View at Google Scholar
  • Meerim Park, Chan-Jeoung Park, Young Wook Cho, Seongsoo Jang, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, and Young Ho Lee, “Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow,” Experimental Hematology, vol. 45, pp. 56–63, 2017. View at Publisher · View at Google Scholar
  • Xinyi Chen, Ruixue Sun, Ting Liu, Yuhuan Zheng, Yu Wu, Jin Chen, and Wenyan Zhang, “Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma,” Oncotarget, vol. 8, no. 68, pp. 112685–112696, 2017. View at Publisher · View at Google Scholar
  • Eva Kriegova, Tomas Pika, Regina Fillerova, Pavel Kromer, Vlastimil Scudla, Petra Schneiderova, Petr Gajdos, Milos Kudelka, Jiri Minarik, and Tomas Papajik, “Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma,” Oncotarget, vol. 8, no. 41, pp. 69408–69421, 2017. View at Publisher · View at Google Scholar
  • Anil K. Deshantri, Aida Varela-Moreira, Veronika Ecker, Sanjay N. Mandhane, Raymond M. Schiffelers, Maike Buchner, and Marcel H.A.M. Fens, “Nanomedicines for the treatment of hematological malignancies,” Journal of Controlled Release, 2018. View at Publisher · View at Google Scholar
  • Ajay K. Nooka, Michael (Luhua) Wang, Andrew J. Yee, Jonathan L. Kaufman, Jooeun Bae, Doris Peterkin, Paul G. Richardson, and Noopur S. Raje, “Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma,” JAMA Oncology, pp. e183267, 2018. View at Publisher · View at Google Scholar
  • Angelina Boccarelli, Flavia Esposito, Mauro Coluccia, Maria Antonia Frassanito, Angelo Vacca, and Nicoletta Del Buono, “Improving knowledge on the activation of bone marrow fibroblasts in MGUS and MM disease through the automatic extraction of genes via a nonnegative matrix factorization approach on gene expression profiles,” Journal of Translational Medicine, vol. 16, no. 1, 2018. View at Publisher · View at Google Scholar
  • Ankit K. Dutta, J. Lynn Fink, John P. Grady, Gareth J. Morgan, Charles G. Mullighan, Luen B. To, Duncan R. Hewett, and Andrew C. W. Zannettino, “Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability,” Leukemia, 2018. View at Publisher · View at Google Scholar
  • Javad Sartakhti, Mohammad Manshaei, and Marco Archetti, “Game Theory of Tumor–Stroma Interactions in Multiple Myeloma: Effect of Nonlinear Benefits,” Games, vol. 9, no. 2, pp. 32, 2018. View at Publisher · View at Google Scholar
  • Sabrina Manni, Marilena Carrino, Gianpietro Semenzato, and Francesco Piazza, “Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance,” International Journal of Molecular Sciences, vol. 19, no. 5, pp. 1512, 2018. View at Publisher · View at Google Scholar
  • Craig T. Wallington-Beddoe, Magdalena Sobieraj-Teague, Bryone J. Kuss, and Stuart M. Pitson, “Resistance to proteasome inhibitors and other targeted therapies in myeloma,” British Journal of Haematology, 2018. View at Publisher · View at Google Scholar
  • Joanna Gariani, Olwen Westerland, Sarah Natas, Hema Verma, Gary Cook, and Vicky Goh, “Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT ( 18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance,” Critical Reviews in Oncology/Hematology, vol. 124, pp. 66–72, 2018. View at Publisher · View at Google Scholar
  • Daniela Belloni, Federico Caligaris-Cappio, Giovanni Tonon, Fabio Ciceri, Magda Marcatti, Stefania Girlanda, Silvia Heltai, Antonello Villa, Barbara Vergani, Lorenza Pecciarini, Marina Ferrarini, Elisabetta Ferrero, and Maurilio Ponzoni, “Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3d surrogate microenvironment,” Haematologica, vol. 103, no. 4, pp. 707–716, 2018. View at Publisher · View at Google Scholar
  • Cosemans Charlotte, Oben Bénedith, Arijs Ingrid, Daniëls Annick, Declercq Jeroen, Vanhees Kimberly, Froyen Guy, Maes Brigitte, Mebis Jeroen, and Rummens Jean-Luc, “Prognostic Biomarkers in the Progression from MGUS to Multiple Myeloma: a Systematic Review,” Clinical Lymphoma Myeloma and Leukemia, 2018. View at Publisher · View at Google Scholar
  • Eilon Krashin, Martin Ellis, Keren Cohen, Maya Viner, Eran Neumark, Gloria Rashid, and Osnat Ashur-Fabian, “Chemical and thyroid hormone profile of the bone marrow interstitial fluid in hematologic disorders and patients without primary hematologic disorders,” Hematological Oncology, 2018. View at Publisher · View at Google Scholar
  • Daphne P. L. Lin, and Crispin R. Dass, “Transdifferentiation of adipocytes to osteoblasts: potential for orthopaedic treatment,” Journal of Pharmacy and Pharmacology, 2018. View at Publisher · View at Google Scholar
  • Ramin Shekarriz, Ghasem Janbabaei, and Saeed Abedian Kenari, “Prognostic value of IL-10 and its relationship with disease stage in Iranian patients with multiple myelom,” Asian Pacific Journal of Cancer Prevention, vol. 19, no. 1, pp. 27–32, 2018. View at Publisher · View at Google Scholar
  • Ying Chen, Jing Zhao, Dengzhe Li, Jinxia Hao, Pengcheng He, Huaiyu Wang, and Mei Zhang, “TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling,” Yonsei Medical Journal, vol. 59, no. 1, pp. 43, 2018. View at Publisher · View at Google Scholar